Trial Profile
A Randomized, Double-blind, Controlled Phase IIb Study of the Safety and Efficacy of ICT-107 in Newly Diagnosed Patients With Glioblastoma Multiforme (GBM) Following Resection and Chemoradiation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs ICT 107 (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors ImmunoCellular Therapeutics
- 18 Jul 2019 Results assessing efficacy and safety of ICT-107 in newly diagnosed glioblastoma patients, published in the Clinical Cancer Research.
- 21 Nov 2016 Results published in an ImmunoCellular Therapeutics Media Release.
- 21 Nov 2016 According to an ImmunoCellular Therapeutics media release, updated immune monitoring data from this trial at the 21st Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology